Mucormycosis: The Scathing Invader.

Area of Science:

• Mycology
• Infectious Diseases
• Ophthalmology

Background:

• Mucormycosis is an invasive fungal infection with increasing incidence, driven by factors like diabetes, malignancy, and immunosuppressant use.
• The COVID-19 pandemic has significantly amplified mucormycosis cases, especially the rhino-orbito-cerebral form, due to factors like corticosteroid use and hypoxia.
• Mucorales fungi, such as Rhizopus oryzae, are ubiquitous, thermotolerant organisms found in various organic substrates.

Purpose of the Study:

• To review the rising incidence of mucormycosis, its clinical forms, and contributing factors, particularly in the context of the COVID-19 pandemic.
• To highlight the common rhino-orbito-cerebral manifestation in COVID-19 patients.
• To emphasize diagnostic methods and current treatment strategies for mucormycosis.

Main Methods:

• Literature review of mucormycosis incidence, risk factors, clinical presentations, and diagnostic/treatment modalities.
• Analysis of the impact of COVID-19 on mucormycosis epidemiology.
• Microscopic identification of Rhizopus oryzae characteristics.

Main Results:

• Mucormycosis incidence is increasing, with COVID-19 exacerbating the surge, particularly the rhino-orbito-cerebral form.
• Key contributing factors include diabetes mellitus, corticosteroid use, hypoxia, and COVID-19 itself.
• Early diagnosis via 10% KOH mount is crucial; Rhizopus oryzae exhibits characteristic hyphal morphology.

Conclusions:

• Effective management of mucormycosis requires a multi-pronged approach including surgical debridement, antifungal therapy (liposomal amphotericin B, posaconazole, isavuconazole), and control of underlying conditions like diabetes and COVID-19.
• Judicious use of corticosteroids and antibiotics is vital during pandemics.
• Prompt diagnosis and aggressive treatment are critical for improving patient outcomes in mucormycosis.